- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular effects of gliptins
Authors
Keywords
-
Journal
Nature Reviews Cardiology
Volume 10, Issue 2, Pages 73-84
Publisher
Springer Nature
Online
2013-01-08
DOI
10.1038/nrcardio.2012.183
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Steven G. Chrysant et al. AMERICAN JOURNAL OF CARDIOLOGY
- Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells
- (2012) Chun-Yao Huang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
- (2012) Robert Klempfner et al. Cardiovascular Diabetology
- Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
- (2012) Michael E Cobble et al. Cardiovascular Diabetology
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
- (2012) Swenja Kröller-Schön et al. CARDIOVASCULAR RESEARCH
- Incretin-based therapies and cardiovascular risk
- (2012) Edoardo Mannucci et al. CURRENT MEDICAL RESEARCH AND OPINION
- GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
- (2012) Dhanwantee Mundil et al. Diabetes & Vascular Disease Research
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
- (2012) S.-C. Liu et al. DIABETES OBESITY & METABOLISM
- Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
- (2012) K. Gooßen et al. DIABETES OBESITY & METABOLISM
- The Effect of Sitagliptin Versus Glibenclamide on Arterial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients
- (2012) Shlomit Koren et al. Diabetes Technology & Therapeutics
- Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
- (2012) B. Eliasson et al. DIABETOLOGIA
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Saxagliptin
- (2012) Lily P.H. Yang DRUGS
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- Cardioprotective Effects of Metformin and Vildagliptin in Adult Rats with Insulin Resistance Induced by a High-Fat Diet
- (2012) Nattayaporn Apaijai et al. ENDOCRINOLOGY
- The Synergistic Effect of Valsartan and LAF237 [(S)-1-[(3-Hydroxy-1-Adamantyl)Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice
- (2012) Min Shen et al. Experimental Diabetes Research
- Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism
- (2012) Limei Liu et al. HYPERTENSION
- Sitagliptin Exerts an Antinflammatory Action
- (2012) Antoine Makdissi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction
- (2012) Simone Post et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Dipeptidyl Peptidase-4 Inhibitor
- (2012) Toyoaki Murohara JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice
- (2012) Junichi Matsubara et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
- (2012) Nancy J. Brown Journal of the American Society of Hypertension
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- The effect of glucagon-like peptide 1 on cardiovascular risk
- (2012) Jacob Sivertsen et al. Nature Reviews Cardiology
- Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers
- (2012) Ashish Kumar Gupta et al. PLATELETS
- The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
- (2011) Benjamin M. Scirica et al. AMERICAN HEART JOURNAL
- EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
- (2011) William B. White et al. AMERICAN HEART JOURNAL
- Ongoing Clinical Trials Evaluating the Cardiovascular Safety and Efficacy of Therapeutic Approaches to Diabetes Mellitus
- (2011) Vivian A. Fonseca AMERICAN JOURNAL OF CARDIOLOGY
- The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
- (2011) Yumei Ye et al. BASIC RESEARCH IN CARDIOLOGY
- Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
- (2011) Sameer Ansar et al. Cardiovascular Diabetology
- Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
- (2011) Meimei Yin et al. Cardiovascular Diabetology
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
- (2011) Zubair Shah et al. CIRCULATION
- Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes
- (2011) Fernando Ovalle CLINICAL THERAPEUTICS
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
- (2011) Sarah Farr et al. CURRENT OPINION IN LIPIDOLOGY
- The role of incretins in salt-sensitive hypertension
- (2011) Tetsuhiro Tanaka et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
- (2011) P. C. M. van Poppel et al. DIABETES CARE
- The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes
- (2011) A. Ceriello et al. DIABETES CARE
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes
- (2011) A. Chaudhuri et al. DIABETES OBESITY & METABOLISM
- Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
- (2011) A. J. Tremblay et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and HbA1c target of
- (2011) K. Esposito et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence
- (2011) R. E. van Genugten et al. DIABETES OBESITY & METABOLISM
- Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials
- (2011) Matteo Monami et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Linagliptin
- (2011) Lesley J. Scott DRUGS
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
- (2011) Roberta Baetta et al. DRUGS
- Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
- (2011) Nelson Gomez et al. EUROPEAN JOURNAL OF HEART FAILURE
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice
- (2011) Nga N Ta et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effects of DPP-4 inhibition on cardiac metabolism and function in mice
- (2011) M. Lenski et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
- (2011) Lyubov Chaykovska et al. PLoS One
- Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
- (2011) Zubair Shah et al. VASCULAR PHARMACOLOGY
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
- (2010) Yumei Ye et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
- (2010) Barbara Huisamen et al. CARDIOVASCULAR DRUGS AND THERAPY
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
- (2010) M. Sauve et al. DIABETES
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
- (2010) E. S. Horton et al. DIABETES CARE
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
- (2010) P. Anagnostis et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- Sitagliptin
- (2010) Sohita Dhillon DRUGS
- Vildagliptin
- (2010) Gillian M. Keating DRUGS
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome
- (2010) Edwin K. Jackson HYPERTENSION
- Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis
- (2010) Hans D. Theiss et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats
- (2010) Bruna PM Pacheco et al. JOURNAL OF HYPERTENSION
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
- (2010) Liliana Ferreira et al. MEDIATORS OF INFLAMMATION
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
- (2010) Walid K.H. Fakhoury et al. PHARMACOLOGY
- SDF-1α as a therapeutic stem cell homing factor in myocardial infarction
- (2010) Santhosh K. Ghadge et al. PHARMACOLOGY & THERAPEUTICS
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes
- (2010) Jitendra Vaghasiya et al. REGULATORY PEPTIDES
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
- (2009) David J Grieve et al. BRITISH JOURNAL OF PHARMACOLOGY
- Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
- (2009) Marc-Michael Zaruba et al. Cell Stem Cell
- Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
- (2009) Marc Vanderheyden et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
- (2009) Mark Kirby et al. CLINICAL SCIENCE
- Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay
- (2009) Kevin Niswender DIABETES OBESITY & METABOLISM
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Diabetes medications and body weight
- (2009) Joanna Mitri et al. Expert Opinion On Drug Safety
- Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
- (2009) Manfredi Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
- (2009) Kiwon Ban et al. Journal of the American Society of Hypertension
- Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
- (2009) Giuseppe Derosa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database
- (2008) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Hypoglycaemia in Type 2 diabetes
- (2008) S. A. Amiel et al. DIABETIC MEDICINE
- Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
- (2008) Michael Boschmann et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Assessing the Cardiovascular Safety of Diabetes Therapies
- (2008) Allison B. Goldfine NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started